CTOs on the Move

Ribon Therapeutics

www.ribontx.com

 
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ribontx.com
  • Building D, 99 Hayden Avenue Suite 100
    99 Hayden Avenue, MA USA 02421
  • Phone: 617.914.8700

Executives

Name Title Contact Details

Funding

Ribon Therapeutics raised $65M on 01/04/2019

Similar Companies

VenatoRx

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company has also been awarded a contract from the NIH and funding from the Wellcome Trust to advance the company’s product candidates.

GeneGo bioinformatics software

GeneGo bioinformatics software, Inc. is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enthalpy Analytical

Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Creo

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.

Coya Therapeutics

The company`s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an `off the shelf` approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson`s, Alzheimer`s, FTD and autoimmune diseases.